New Test Detects The Spread Of Prostate Cancer Cells With Greater Accuracy

August 13, 1997

One of the major questions for people diagnosed with cancer is whether the cancer has spread. A new test is now available for men with prostate cancer to more accurately find cancerous cells that have spread to lymph nodes anywhere in the body. Doctors at the University of Maryland Medical Center are among the first in the U.S. to use the test, which helps patients receive the best treatment and avoid unnecessary surgery.

"This new test, called ProstaScint, fills a void," says Salma Khan, M.D. a nuclear medicine specialist at the University of Maryland Medical Center, where the test has been performed on 18 patients. "It gives us more information and helps us to determine the best course of therapy for each patient," says Dr. Khan, who is also an assistant professor of radiology at the University of Maryland School of Medicine.

The test uses a monoclonal antibody designed to find and attach itself to the wall of prostate cancer cells. The antibody is combined with a radioactive tracer, indium 111, to form a drug that is injected into a patient. After four days, the patient's body is scanned. Lymph nodes that have been invaded by prostate cancer cells appear as "hot spots" on the test. Through this analysis, doctors can determine whether the cancer has remained local, within the prostate, or if it has spread to lymph nodes anywhere in the body. It can find tumors within lymph nodes as small as a quarter of an inch in length.

The ProstaScint is useful in patients with newly diagnosed prostate cancer to help decide if they should have surgery to remove the prostate. The test also helps post-surgical patients with rising blood levels of prostate specific antigen (PSA), to determine where the cancer may have spread. Before this test was available, patients received a CT scan. That test only detects enlarged lymph nodes once they reach about one-third of an inch in size, and does not reveal whether the nodes are enlarged because of cancer.

"This new test will help us determine which patients should undergo surgery," says Stephen Jacobs, M.D., professor of surgery and head of urology at the University of Maryland Medical Center. "If the cancer has spread, surgical removal of the prostate would not cure the disease. Patients whose cancer has spread outside the prostate gland may benefit from radiation therapy. And if cancer is evident in the lymph nodes outside of the pelvis, hormonal therapy may be the best treatment," says Dr. Jacobs, who is also co-director of the Urologic Oncology Program at the University of Maryland's Greenebaum Cancer Center.

According to the American Cancer Society, about 317,000 men in the U.S. were diagnosed with prostate cancer in 1996. It is the most common type of cancer in men.

The test was approved by the FDA in late 1996. Since then, selected sites around the country, including the University of Maryland Medical Center, have been performing ProstaScint. Each hospital must go through an accreditation process prior to becoming certified to perform the exam.

Other antibody tracer exams are currently used for diagnosis of colorectal, lung, and ovarian cancer. Studies are underway to evaluate use of antibody tracer tests for patients with breast cancer and lymphoma.

The University of Maryland's Greenebaum Cancer Center provides a full spectrum of diagnosis and treatment options for patients with prostate and other urologic cancers.

University of Maryland Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to